Prelude Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$4.44(as of Apr 17, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Prelude Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$4.44
Ticker SymbolPRLD
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees79
CountyUSA
Market Cap$278.5M

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Prelude Therapeutics Inc In Our Stock Scanner

As of Apr 17, 2026
As of ---
As of ---
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.